Related Experiment Video
Updated: Jul 14, 2026

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
Published on: April 9, 2012
[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical
María Paloma Geijo1, Carmen Rosa Herranz, David Vaño
1Sección de Medicina Interna-Infecciosas, Hospital General Virgen de la Luz, Cuenca, España. mgeijo@sescam.jccm.es
Introduction:
The aim of this study was to compare the adherence to, and side effects of a 3-month short-course treatment for latent tuberculosis infection as compared to the standard 6-month course.
Methods:
Prospective, comparative, randomized, open trial including patients with a positive tuberculin skin test and appropriate criteria for treatment in accordance with the CDC guidelines, and excluding patients with HIV infection. Group I (6H) was assigned to isoniazid 300 mg per day for 6 months and Group II (3HR) was assigned to isoniazid 300 mg per day plus rifampin 600 mg per day for 3 months. The patients were followed up for five years.
Results:
A total of 105 patients were included, among which 9 refused treatment; 45 patients were placed in Group I and 51 patients in Group II. Both groups were comparable at baseline. Hepatotoxicity was 44% in Group 6H and 29% in Group 3HR (P = 0.07). Hepatotoxicity was severe in 6.7% of Group 6H and 5.8% of Group 3HR, requiring treatment interruption in 4.4% and 1.9%, respectively (P = NS). Among the total, 75.6% of patients in group 6H, and 90.2% in group 3HR completed the study treatment (P = 0.05). Tuberculous disease was detected in only one patient in the 6H group, occurring in the second month of treatment.
Conclusion:
In the treatment of latent tuberculosis infection, a 3-month course of isoniazid plus rifampin resulted in better adherence and a lower percentage of discontinued treatments than a 6-month isoniazid course. Tolerance was similar in the two regimens.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis